Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 17/20 | 0.38 |
| ▸ | FLT1 | P17948 | 12/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2282096 | 0.83 | MEN1 (0.39) | MAPTKDRFLT1PDGFRBPDGFRA | |
| SCHEMBL2285231 | 0.80 | GRIN3B (0.35) | KDRFLT1 | |
| SCHEMBL2284437 | 0.79 | SMN1; SMN2 (0.33) | KDRFLT1 | |
| SCHEMBL2282899 | 0.74 | KDR (0.38) | NPC1MAPTHTTRAB9AL3MBTL1 | |
| SCHEMBL2280273 | 0.74 | MPO (0.34) | KDRFLT1PDGFRBPDGFRA | |
| SCHEMBL18418112 | 0.73 | MAPT (0.36) | NPC1MAPTHTTRAB9AL3MBTL1 | |
| SCHEMBL18418120 | 0.73 | KDR (0.38) | NPC1MAPTHTTRAB9AL3MBTL1 | |
| SCHEMBL2602329 | 0.72 | KDR (0.40) | MAPTKDRFLT1PDGFRBPDGFRA | |
| SCHEMBL167759 | 0.72 | PDGFRB (0.71) | KDRPDGFRBPDGFRA | |
| SCHEMBL13186320 | 0.71 | GRIN2D (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-1989211-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | Array Biopharma, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008063202-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | NPC1 1260/4885MAPT 4444/4885HTT 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.